Whereas, there were no significant difference in CD3+ T lymphocyte percentage, CD3/CD8+ T lymphocyte percentage, or CD19+ B lymphocyte percentage between the two groups

Whereas, there were no significant difference in CD3+ T lymphocyte percentage, CD3/CD8+ T lymphocyte percentage, or CD19+ B lymphocyte percentage between the two groups. Correlations between serum complement levels and clinical characteristics, lymphocyte profile Spearman correlation coefficient analysis was performed to investigate the association between serum complement level and ESSDAI, laboratory parameters and lymphocyte profile in total patients at baseline. renal, and nervous system involvement, and received more immunosuppressant treatments than NC group (< 0.05). ESSDAI score TX1-85-1 was significantly higher in patients with HC (< 0.05). Multivariate logistic analysis indicated that leukopenia (OR = 2.23) and hyper-IgG (OR = 2.13) were independent risk factors for pSS with HC. In addition, profound CD16/CD56+ NK-cell lymphopenia was found in pSS-HC patients. More pSS patients developed SLE in the HC group TX1-85-1 than NC group (4.76% vs. 0.80%, = 0.04) during the follow-up. Conclusion HC was not an uncommon manifestation of pSS and had an independent association with the main clinical TX1-85-1 and immunological features. Patients with pSS-HC had an increased possibility to develop SLE that required more positive treatment with glucocorticoids and immunosuppressants. Key Points: ? The pSS patients with hypocomplementemia had an increased possibility to develop SLE.< 0.05. Results Prevalence of HC in patients with pSS The study cohort consisted of 333 patients (310 women and 23 men). The HC rate was 25.23% (84/333). Among the 84 patients with pSS with HC, 78 (92.86%) were women and 6 (7.14%) were men. Those with HC were younger than those without (49.86 15.49 vs. 55.30 12.38 years; = 0.004). Laboratory characteristics As shown in Table ?Table1,1, the patients with pSS with HC had striking significant differences between the two groups concerning the white blood cell (WBC) count (< 0.001), in particular the neutrophil and lymphocyte counts (= 0.003 and = 0.005, respectively). The C-reactive protein (CRP) level was lower in patients with pSS-HC than in those with normal complement levels (< 0.001), although the CRP level was approximately in a normal range. Additionally, the serum rheumatoid factor (RF) level (21.90 [10.6C158] vs. 16.55 [10.60C55.93]) was higher in the HC than in the normocomplementemia (NC) group, but the difference was not statistically significant (= 0.44). Moreover, higher serum immunoglobulin G (IgG) levels were observed in the HC than in the NC group (< 0.001). Further, higher presence of IgG (53.57% vs. 30.04%, < 0.001) and anti-Ro52 positivity (71.43% vs. 56.22%, = 0.01) were observed in patients with HC. Whereas, the positive rates of detecting antinuclear antibodies (ANA), ACA, anti-Ro/SSA, anti-La/SSB, and anti-RNP antibodies were not significantly different between the two groups. Besides, no significant difference in histologic evaluation of minor salivary gland, as a focus score 1, was observed between the two groups. Table 1 Demographic and serological descriptors of patients with pSS with HC and NC = 333)= 84)= 249)value: HC group vs. NC group; *Positive RF > 20 IU/mL; **positive for ANA titers 1:320 Complement and autoantibodies In the pSS cohort, the levels of serum C3 and C4 in anti-Ro/SSA-positive were 1.02 (0.89C1.20) g/L and 0.18 (0.15C0.23) g/L, which were significantly lower than anti-Ro/SSA-negative patients (1.11 (0.96C1.22) g/L, = 0.006; 0.20 (0.17C0.24) g/L, = 0.004; respectively). When further stratifying for the presence or absence of anti-La/SSB antibodies, the level of serum C4 in anti-La/SSB-positive was significantly lower than anti-La/SSB-negative patients (0.16 (0.13C0.23) g/L vs. 0.20 (0.17C0.24) g/L, = 0.001). In addition, no significant difference in complement C3 was observed between anti-La/SSB-positive and anti-La/SSB-negative patients at baseline. Whereas, at baseline, Rabbit Polyclonal to Trk C (phospho-Tyr516) no significant differences in complement C3 and C4 were observed between RF-positive and RF-negative nor ANA-positive and ANA-negative patients (Supplementary Fig. 1). Clinical manifestations In our study, the patients with pSS with HC more commonly exhibited hematological involvement (67.86% vs. 51.41%; = 0.009), thrombocytopenia (11.90% vs. 4.02%; = 0.009), leukopenia (33.33% vs. 14.46%; < 0.001) and lymphopenia (36.90% vs. 22.89%; = 0.01) at pSS diagnosis (Fig. ?(Fig.11 and Supplementary.